Business
TerrAscend announces results of annual general meeting
TerrAscend announces results of annual general meeting Canada NewsWire TORONTO, ...
About this update from Terrascend Corp.
[{"type":"text","content":"\n\n\n\nTerrAscend announces results of annual general meeting\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, May 29, 2019\n\n\n\nTORONTO, May 29, 2019 /CNW/ - TerrAscend Corp. (CSE:TER; OTCQX: TRSSF) (\"TerrAscend\" or the \"Company\") is pleased to announce that the nominees set forth in the Company's management information circular dated April 24, 2019, Mr. Craig Collard, Mr. Richard Mavrinac, Dr. Michael Nashat, Ms. Lisa Swartzman and Mr. Jason Wild, were elected as directors of the Company at the annual meeting of shareholders held today (the \"Meeting\"). At the Meeting, shareholders also approved the re-appointment of MNP LLP as the auditor of the Company and the authorization of the Company's board of directors to fix the auditor's remuneration.\n\n \n \n\n \nAbout TerrAscend\nTerrAscend provides quality products, brands, and services to the global cannabinoid market. As the first North American Operator (NAO), with scale operations in both Canada and the US, the Company participates in the medical and legal adult use market across Canada and in several US states where cannabis has been legalized for therapeutic or adult use. Additionally, TerrAscend will soon be the first and only cannabis company with sales in the US, Canada, and Europe as it has received EU GMP certification for its manufacturing facility in Mississauga, Ontario. TerrAscend operates a number of synergistic businesses, including Arise Bioscience Inc., a manufacturer and distributor of hemp-derived products; Ascendant Laboratories Inc., a biotechnology and licensing company committed to the continuous improvement of cannabinoid expressing plants; and Solace RX Inc., a proposed Drug Preparation Premises (DPP) focused on the development of novel formulations and delivery forms. \nCaution Regarding Cannabis Operations in the United States\nInvestors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States.  Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it ill...